Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Liquidia Corporation (NASDAQ:LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by United Therapeutics Corporation (United Therapeutics) with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil Injection is manufactured by Sandoz Inc. (Sandoz) and was launched as the first-to-file, fully-substitutable generic treprostinil for parenteral administration in March 2019. Liquidia PAH, LLC (formerly known as RareGen), a wholly owned subsidiary of Liquidia (Liquidia PAH), partnered with Sandoz in August 2018 on an exclusive basis to market and commercialize Treprostinil Injection.
爲罕見心肺疾病患者開發創新療法的生物製藥公司Liquidia Corporation（納斯達克股票代碼：LQDA）（Liquidia）今天宣佈，美國新澤西地區地方法院（地方法院）認定，聯合療法公司（United Therapeutics）干預仿製藥的推出造成了超過1.37億美元的損失。曲前列斯尼注射液由山德士公司（Sandoz）製造，於2019年3月作爲首款完全可替代的腸胃外給藥仿製曲前列斯尼上市。Liquidia（Liquidia PAH）的全資子公司Liquidia PAH, LLC（前身爲RareGen）於2018年8月與山德士合作，獨家銷售和商業化了曲普司尼注射液。